Optimising Antimicrobial Selection and Duration in the Treatment of Febrile Neutropenia in Children

Research output: Contribution to journalReview articlepeer-review

Standard

Optimising Antimicrobial Selection and Duration in the Treatment of Febrile Neutropenia in Children. / Morgan, Jessica E; Phillips, Bob; Haeusler, Gabrielle M; Chisholm, Julia C.

In: Infection and drug resistance, Vol. 14, 30.03.2021, p. 1283-1293.

Research output: Contribution to journalReview articlepeer-review

Harvard

Morgan, JE, Phillips, B, Haeusler, GM & Chisholm, JC 2021, 'Optimising Antimicrobial Selection and Duration in the Treatment of Febrile Neutropenia in Children', Infection and drug resistance, vol. 14, pp. 1283-1293. https://doi.org/10.2147/IDR.S238567

APA

Morgan, J. E., Phillips, B., Haeusler, G. M., & Chisholm, J. C. (2021). Optimising Antimicrobial Selection and Duration in the Treatment of Febrile Neutropenia in Children. Infection and drug resistance, 14, 1283-1293. https://doi.org/10.2147/IDR.S238567

Vancouver

Morgan JE, Phillips B, Haeusler GM, Chisholm JC. Optimising Antimicrobial Selection and Duration in the Treatment of Febrile Neutropenia in Children. Infection and drug resistance. 2021 Mar 30;14:1283-1293. https://doi.org/10.2147/IDR.S238567

Author

Morgan, Jessica E ; Phillips, Bob ; Haeusler, Gabrielle M ; Chisholm, Julia C. / Optimising Antimicrobial Selection and Duration in the Treatment of Febrile Neutropenia in Children. In: Infection and drug resistance. 2021 ; Vol. 14. pp. 1283-1293.

Bibtex - Download

@article{556651607792415eb3dd950a91001e19,
title = "Optimising Antimicrobial Selection and Duration in the Treatment of Febrile Neutropenia in Children",
abstract = "Febrile neutropenia (FN) is a frequent complication of cancer treatment in children. Owing to the potential for overwhelming bacterial sepsis, the recognition and management of FN requires rapid implementation of evidenced-based management protocols. Treatment paradigms have progressed from hospitalisation with broad spectrum antibiotics for all patients, through to risk adapted approaches to management. Such risk adapted approaches aim to provide safe care through incorporating antimicrobial stewardship (AMS) principles such as implementation of comprehensive clinical pathways incorporating de-escalation strategies with the imperative to reduce hospital stay and antibiotic exposure where possible in order to improve patient experience, reduce costs and diminish the risk of nosocomial infection. This review summarises the principles of risk stratification in FN, the current key considerations for optimising empiric antimicrobial selection including knowledge of antimicrobial resistance patterns and emerging technologies for rapid diagnosis of specific infections and summarises existing evidence on time to treatment, investigations required and duration of treatment. To aid treating physicians we suggest the key features based on current evidence that should be part of any FN management guideline and highlight areas for future research. The focus is on treatment of bacterial infections although fungal and viral infections are also important in this patient group.",
author = "Morgan, {Jessica E} and Bob Phillips and Haeusler, {Gabrielle M} and Chisholm, {Julia C}",
note = "{\textcopyright} 2021 Morgan et al.",
year = "2021",
month = mar,
day = "30",
doi = "10.2147/IDR.S238567",
language = "English",
volume = "14",
pages = "1283--1293",
journal = "Infection and drug resistance",
issn = "1178-6973",
publisher = "Dove Medical Press Ltd.",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Optimising Antimicrobial Selection and Duration in the Treatment of Febrile Neutropenia in Children

AU - Morgan, Jessica E

AU - Phillips, Bob

AU - Haeusler, Gabrielle M

AU - Chisholm, Julia C

N1 - © 2021 Morgan et al.

PY - 2021/3/30

Y1 - 2021/3/30

N2 - Febrile neutropenia (FN) is a frequent complication of cancer treatment in children. Owing to the potential for overwhelming bacterial sepsis, the recognition and management of FN requires rapid implementation of evidenced-based management protocols. Treatment paradigms have progressed from hospitalisation with broad spectrum antibiotics for all patients, through to risk adapted approaches to management. Such risk adapted approaches aim to provide safe care through incorporating antimicrobial stewardship (AMS) principles such as implementation of comprehensive clinical pathways incorporating de-escalation strategies with the imperative to reduce hospital stay and antibiotic exposure where possible in order to improve patient experience, reduce costs and diminish the risk of nosocomial infection. This review summarises the principles of risk stratification in FN, the current key considerations for optimising empiric antimicrobial selection including knowledge of antimicrobial resistance patterns and emerging technologies for rapid diagnosis of specific infections and summarises existing evidence on time to treatment, investigations required and duration of treatment. To aid treating physicians we suggest the key features based on current evidence that should be part of any FN management guideline and highlight areas for future research. The focus is on treatment of bacterial infections although fungal and viral infections are also important in this patient group.

AB - Febrile neutropenia (FN) is a frequent complication of cancer treatment in children. Owing to the potential for overwhelming bacterial sepsis, the recognition and management of FN requires rapid implementation of evidenced-based management protocols. Treatment paradigms have progressed from hospitalisation with broad spectrum antibiotics for all patients, through to risk adapted approaches to management. Such risk adapted approaches aim to provide safe care through incorporating antimicrobial stewardship (AMS) principles such as implementation of comprehensive clinical pathways incorporating de-escalation strategies with the imperative to reduce hospital stay and antibiotic exposure where possible in order to improve patient experience, reduce costs and diminish the risk of nosocomial infection. This review summarises the principles of risk stratification in FN, the current key considerations for optimising empiric antimicrobial selection including knowledge of antimicrobial resistance patterns and emerging technologies for rapid diagnosis of specific infections and summarises existing evidence on time to treatment, investigations required and duration of treatment. To aid treating physicians we suggest the key features based on current evidence that should be part of any FN management guideline and highlight areas for future research. The focus is on treatment of bacterial infections although fungal and viral infections are also important in this patient group.

U2 - 10.2147/IDR.S238567

DO - 10.2147/IDR.S238567

M3 - Review article

C2 - 33833534

VL - 14

SP - 1283

EP - 1293

JO - Infection and drug resistance

JF - Infection and drug resistance

SN - 1178-6973

ER -